The gut microbiota in multiple sclerosis varies with disease activity
Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an alt...
Uloženo v:
| Vydáno v: | Genome medicine Ročník 15; číslo 1; s. 1 - 17 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
05.01.2023
BioMed Central Ltd BMC |
| Témata: | |
| ISSN: | 1756-994X, 1756-994X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known.
Methods
Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity.
Results
We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of
IL17A
and
IL6
was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species,
Faecalibacterium prausnitzii
and
Gordonibacter urolithinfaciens
, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of
Caudovirales
bacteriophages
.
Conclusions
Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. |
|---|---|
| AbstractList | Abstract Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Methods Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. Results We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages. Conclusions Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Background : Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Methods : Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. Results : We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens , whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages . Conclusions :Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Methods Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. Results We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens , whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages . Conclusions Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages. Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-[beta], IL-33, and TNF-[alpha]. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages. Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known.BACKGROUNDMultiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known.Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity.METHODSHere, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity.We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages.RESULTSWe found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages.Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials.CONCLUSIONSConsiderable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known. Methods Here, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity. Results We found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-[beta], IL-33, and TNF-[alpha]. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages. Conclusions Considerable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials. Keywords: Multiple sclerosis, Shotgun sequencing, Gut microbiota, Gordonibacter urolithinfaciens, Faecalibacterium prausnitzii |
| ArticleNumber | 1 |
| Audience | Academic |
| Author | Pons, Nicolas Quinquis, Benoit Stankevic, Evelina Oturai, Annette Sørensen, Per Soelberg Forslund, Sofia K. Fan, Yong Dantoft, Thomas M. Poulsen, Casper S. Pedersen, Oluf Vestergaard, Henrik Hansen, Torben Sellebjerg, Finn Brix, Susanne Hansen, Tue H. Ehrlich, Stanislav D. Thirion, Florence Levenez, Florence Lyu, Liwei Søndergaard, Helle B. |
| Author_xml | – sequence: 1 givenname: Florence surname: Thirion fullname: Thirion, Florence organization: Université Paris-Saclay, INRAE, MGP – sequence: 2 givenname: Finn surname: Sellebjerg fullname: Sellebjerg, Finn organization: Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Department of Clinical Medicine, University of Copenhagen – sequence: 3 givenname: Yong surname: Fan fullname: Fan, Yong organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 4 givenname: Liwei surname: Lyu fullname: Lyu, Liwei organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 5 givenname: Tue H. surname: Hansen fullname: Hansen, Tue H. organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 6 givenname: Nicolas surname: Pons fullname: Pons, Nicolas organization: Université Paris-Saclay, INRAE, MGP – sequence: 7 givenname: Florence surname: Levenez fullname: Levenez, Florence organization: Université Paris-Saclay, INRAE, MGP – sequence: 8 givenname: Benoit surname: Quinquis fullname: Quinquis, Benoit organization: Université Paris-Saclay, INRAE, MGP – sequence: 9 givenname: Evelina surname: Stankevic fullname: Stankevic, Evelina organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 10 givenname: Helle B. surname: Søndergaard fullname: Søndergaard, Helle B. organization: Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet – sequence: 11 givenname: Thomas M. surname: Dantoft fullname: Dantoft, Thomas M. organization: Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg University Hospital – sequence: 12 givenname: Casper S. surname: Poulsen fullname: Poulsen, Casper S. organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 13 givenname: Sofia K. surname: Forslund fullname: Forslund, Sofia K. organization: Experimental and Clinical Research Center, A Cooperation of Charité–Universitätsmedizin and the Max-Delbrück Center, Max Delbrück Center for Molecular Medicine (MDC), Charité–Universitätsmedizin Berlin, DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Structural and Computational Biology Unit, European Molecular Biology Laboratory – sequence: 14 givenname: Henrik surname: Vestergaard fullname: Vestergaard, Henrik organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Department of Medicine, Rønne Hospital – sequence: 15 givenname: Torben surname: Hansen fullname: Hansen, Torben organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen – sequence: 16 givenname: Susanne surname: Brix fullname: Brix, Susanne organization: Department of Biotechnology and Biomedicine, Technical University of Denmark – sequence: 17 givenname: Annette surname: Oturai fullname: Oturai, Annette organization: Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet – sequence: 18 givenname: Per Soelberg surname: Sørensen fullname: Sørensen, Per Soelberg organization: Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet – sequence: 19 givenname: Stanislav D. surname: Ehrlich fullname: Ehrlich, Stanislav D. organization: Université Paris-Saclay, INRAE, MGP, Department of Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology – sequence: 20 givenname: Oluf orcidid: 0000-0002-3321-3972 surname: Pedersen fullname: Pedersen, Oluf email: oluf@sund.ku.dk organization: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Center for Clinical Metabolic Research, Herlev-Gentofte University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36604748$$D View this record in MEDLINE/PubMed https://hal.inrae.fr/hal-04300520$$DView record in HAL |
| BookMark | eNp9UltrFDEUHqRiL_oHfJABQfRham6by0thKdUWCr5U8C1kctnJMjtZk8xK_72ZTi27RUoeEk6-yznJd1odDWGwVfUegnMIOf2aIAYMNwChBkBIeANfVSeQLWgjBPl1tHc-rk5TWgNACSLsTXWMKQWEEX5SXd11tl6Nud54HUPrQ1a1H-rN2Ge_7W2ddG9jSD7VOxW9TfUfn7va-GRVsrXS2e98vn9bvXaqT_bd435W_fx2dXd53dz--H5zubxtNCUkN44rpK3myiLCCWgVax0SlHMjCMEQGegAbJ2hmCENLGktMw7iFghqAFYOn1U3s64Jai230W9UvJdBeflQCHElVcy-9CwFopQZAZ2giKhWtQuHNV5g0XIKDYJF62LW2o7txhpthxxVfyB6eDP4Tq7CTgoOCWS8CHyZBbpntOvlrZxqgGAAFgjsJrPPj2Yx_B5tynLjk7Z9rwYbxiQRo1CwBaST7McZulJlDD-4UNz1BJdLhhEWHGBaUOf_QZVlbPnJkhPnS_2A8GmP0FnV5y6Ffsw-DOkQ-GH_XZ4m-5eZAkAzoAQmpWjdEwQCOQVTzsGUJZjyIZhyegD-jKR9VpN56dv3L1PxTE3FZ1jZKNdhjEPJ2Uusvw_y9Mw |
| CitedBy_id | crossref_primary_10_2147_DDDT_S489454 crossref_primary_10_7759_cureus_84687 crossref_primary_10_1016_j_mib_2024_102494 crossref_primary_10_3390_nu16040501 crossref_primary_10_3389_fimmu_2025_1582119 crossref_primary_10_3390_brainsci15030253 crossref_primary_10_1007_s00210_024_03496_8 crossref_primary_10_3390_biomedicines12071392 crossref_primary_10_3389_fimmu_2024_1451742 crossref_primary_10_1016_j_msard_2024_106151 crossref_primary_10_3389_fimmu_2023_1260663 crossref_primary_10_1038_s41392_024_01946_6 crossref_primary_10_1080_19490976_2024_2401654 crossref_primary_10_3389_fimmu_2023_1176016 crossref_primary_10_1016_j_nbd_2025_106956 crossref_primary_10_3390_cells14120871 crossref_primary_10_3390_ijms25063198 crossref_primary_10_1186_s12883_025_04187_4 crossref_primary_10_3389_fcimb_2025_1585020 crossref_primary_10_3390_ijms241914756 crossref_primary_10_1080_17582024_2024_2435249 crossref_primary_10_4103_1673_5374_387965 crossref_primary_10_1016_j_celrep_2025_116297 crossref_primary_10_1186_s12974_024_03139_y crossref_primary_10_1038_s41598_024_64369_x crossref_primary_10_1016_j_msard_2025_106366 crossref_primary_10_1007_s12602_023_10089_z crossref_primary_10_1111_imr_13343 crossref_primary_10_1007_s12602_024_10274_8 crossref_primary_10_3389_fnins_2025_1506566 crossref_primary_10_1016_j_ejmech_2025_117931 crossref_primary_10_1016_j_nexres_2025_100441 crossref_primary_10_1038_s41564_025_02064_x crossref_primary_10_17116_jnevro202312307296 crossref_primary_10_1016_j_jneuroim_2025_578696 crossref_primary_10_2196_64894 crossref_primary_10_1002_eji_202250236 crossref_primary_10_1016_j_msard_2024_105762 crossref_primary_10_3390_ijms26073412 crossref_primary_10_1002_jwmg_22545 crossref_primary_10_1080_19490976_2024_2387794 crossref_primary_10_3389_fmicb_2025_1486661 crossref_primary_10_3389_fimmu_2025_1514762 crossref_primary_10_3390_biology14040435 crossref_primary_10_3389_fmicb_2025_1583562 crossref_primary_10_3389_fimmu_2025_1513599 crossref_primary_10_1515_tnsci_2025_0371 crossref_primary_10_3389_fnut_2023_1328426 crossref_primary_10_1007_s12035_025_05194_9 crossref_primary_10_1016_j_foodcont_2024_110465 crossref_primary_10_3389_fimmu_2024_1475126 crossref_primary_10_1186_s12883_023_03522_x crossref_primary_10_1016_j_brainresbull_2024_110883 crossref_primary_10_1016_j_clnu_2024_03_029 crossref_primary_10_1038_s41564_023_01355_5 crossref_primary_10_1016_j_sjbs_2024_103939 crossref_primary_10_3390_biomedicines13081806 crossref_primary_10_3389_fnins_2025_1623165 crossref_primary_10_1016_j_neuroscience_2025_07_024 crossref_primary_10_1007_s12035_024_04270_w crossref_primary_10_1007_s40263_023_00986_w crossref_primary_10_1016_j_ejphar_2024_177080 |
| Cites_doi | 10.1038/nature12506 10.1093/nar/gkv1070 10.1111/imm.12552 10.1111/ane.13045 10.1146/annurev-immunol-031210-101312 10.1038/nature08821 10.3389/fimmu.2021.661493 10.1038/s41586-021-04177-9 10.1038/nature10554 10.1016/S0140-6736(18)30481-1 10.1016/j.jns.2016.02.042 10.1093/nar/gkv1248 10.1093/bioinformatics/bty830 10.1038/nmeth.3176 10.1038/ncomms12015 10.1016/j.tins.2020.06.002 10.1016/j.bbalip.2018.05.009 10.15454/FLANUP 10.1016/j.ygeno.2013.07.011 10.1016/S0140-6736(16)32388-1 10.1016/S1474-4422(19)30356-4 10.1002/ana.24901 10.1111/ane.12712 10.1007/978-1-4939-8850-1 10.3389/fnut.2020.610946 10.1016/j.neuron.2018.01.021 10.1099/ijs.0.055095-0 10.1073/pnas.1711233114 10.1093/nar/gku1207 10.3389/fimmu.2020.00379 10.1371/journal.pcbi.1009442 10.1186/s12864-019-5699-9 10.1093/nar/29.1.41 10.1016/j.immuni.2015.09.007 10.3389/fimmu.2020.578648 10.1038/nmeth.1923 10.1172/JCI143774 10.1093/brain/awab320 10.1038/nbt.3960 10.1177/0963689719873890 10.1016/j.ebiom.2021.103798 10.1002/acn3.51441 10.1111/nmo.14326 10.1038/nmicrobiol.2016.88 10.3389/fimmu.2021.676016 10.2147/CLEP.S129335 10.1186/s13059-017-1271-6 10.1186/s12967-021-02995-z 10.1084/jem.20180448 10.1038/s41564-018-0337-x 10.1038/s41467-020-15457-9 10.1056/NEJMra1401483 10.1371/journal.pone.0264556 10.1212/WNL.0000000000000560 10.1016/S1474-4422(17)30470-2 10.3389/fimmu.2019.00462 10.1126/sciadv.abd4595 10.1016/j.msard.2019.101427 10.1177/1352458519872664 10.1016/j.cell.2020.02.035 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. Attribution |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: Attribution |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s13073-022-01148-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1756-994X |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_92667d91f9624abab5f3c3539b861d21 PMC9814178 oai:HAL:hal-04300520v1 A732398036 36604748 10_1186_s13073_022_01148_1 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GrantInformation_xml | – fundername: Metagenopolis grant grantid: ANR-11-DPBS-0001 – fundername: Danish Multiple Sclerosis Society – fundername: Novo Nordisk Fonden funderid: http://dx.doi.org/10.13039/501100009708 – fundername: ; – fundername: ; grantid: ANR-11-DPBS-0001 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACJQM ACUHS ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIAM BBNVY BENPR BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 LK8 M1P M7P MK0 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ TUS UKHRP AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 1XC AHSBF EJD H13 HZ~ VOOES 5PM |
| ID | FETCH-LOGICAL-c644t-f8a2cec8ae24840ba7bf29688d944312d1f01bfd6372c0e4be7df13b096d03af3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 71 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000909533900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-994X |
| IngestDate | Fri Oct 03 12:49:05 EDT 2025 Tue Nov 04 02:06:42 EST 2025 Tue Oct 14 20:45:53 EDT 2025 Thu Sep 04 16:40:58 EDT 2025 Tue Nov 11 10:31:02 EST 2025 Tue Nov 04 17:49:33 EST 2025 Thu May 22 21:21:04 EDT 2025 Mon Jul 21 05:59:59 EDT 2025 Sat Nov 29 06:05:15 EST 2025 Tue Nov 18 22:32:05 EST 2025 Sat Sep 06 07:28:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Gut microbiota Shotgun sequencing Multiple sclerosis Gordonibacter urolithinfaciens Faecalibacterium prausnitzii |
| Language | English |
| License | 2022. The Author(s). Attribution: http://creativecommons.org/licenses/by Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c644t-f8a2cec8ae24840ba7bf29688d944312d1f01bfd6372c0e4be7df13b096d03af3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3321-3972 |
| OpenAccessLink | https://link.springer.com/10.1186/s13073-022-01148-1 |
| PMID | 36604748 |
| PQID | 2761975168 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_92667d91f9624abab5f3c3539b861d21 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9814178 hal_primary_oai_HAL_hal_04300520v1 proquest_miscellaneous_2761975168 gale_infotracmisc_A732398036 gale_infotracacademiconefile_A732398036 gale_healthsolutions_A732398036 pubmed_primary_36604748 crossref_primary_10_1186_s13073_022_01148_1 crossref_citationtrail_10_1186_s13073_022_01148_1 springer_journals_10_1186_s13073_022_01148_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-05 |
| PublicationDateYYYYMMDD | 2023-01-05 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Genome medicine |
| PublicationTitleAbbrev | Genome Med |
| PublicationTitleAlternate | Genome Med |
| PublicationYear | 2023 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | C Baecher-Allan (1148_CR3) 2018; 97 AJ Thompson (1148_CR28) 2018; 17 A Mikami (1148_CR55) 2020; 7 DH Haft (1148_CR41) 2001; 29 A Criscuolo (1148_CR33) 2013; 102 1148_CR43 M Valles-Colomer (1148_CR45) 2019; 4 S Jangi (1148_CR58) 2016; 7 R Busto (1148_CR60) 2018; 1863 J Huerta-Cepas (1148_CR40) 2016; 44 1148_CR48 MV Selma (1148_CR61) 2014; 64 L Belbasis (1148_CR8) 2020; 26 1148_CR49 M Yadav (1148_CR68) 2022; 17 SK Shahi (1148_CR18) 2020; 11 A Ntranos (1148_CR67) 2022; 145 A Olsson (1148_CR23) 2021; 12 H Mallick (1148_CR54) 2021; 17 F Zhu (1148_CR59) 2020; 11 K Berer (1148_CR15) 2017; 114 G Schepici (1148_CR26) 2019; 28 A Mirza (1148_CR25) 2020; 37 1148_CR70 1148_CR71 1148_CR7 1148_CR31 1148_CR32 DS Reich (1148_CR1) 2018; 378 H Tremlett (1148_CR27) 2017; 81 PI Costea (1148_CR30) 2017; 35 F Plaza Oñate (1148_CR37) 2019; 35 1148_CR38 X Lin (1148_CR65) 2021; 19 B Langmead (1148_CR35) 2012; 9 T Ogita (1148_CR56) 2020; 11 P Melbye (1148_CR20) 2019; 139 E Le Chatelier (1148_CR36) 2013; 500 JF Cryan (1148_CR10) 2020; 19 SK Shahi (1148_CR17) 2019; 10 K Berer (1148_CR14) 2011; 479 M Kanehisa (1148_CR39) 2016; 44 C Cantoni (1148_CR24) 2022; 76 AJ Thompson (1148_CR2) 2018; 391 D Tobin (1148_CR66) 2021; 12 A Kadowaki (1148_CR13) 2020; 43 MK Horton (1148_CR21) 2021; 8 SK Forslund (1148_CR52) 2021; 600 1148_CR64 JR Brister (1148_CR47) 2015; 43 W Ouyang (1148_CR16) 2011; 29 SP Soelberg (1148_CR6) 2017; 136 1148_CR69 B Buchfink (1148_CR42) 2015; 12 FD Lublin (1148_CR4) 2014; 83 G Comi (1148_CR5) 2017; 389 AC Wing (1148_CR62) 2016; 147 1148_CR50 J Durack (1148_CR11) 2019; 216 1148_CR51 1148_CR53 1148_CR12 J Qin (1148_CR9) 2010; 464 S Vieira-Silva (1148_CR44) 2016; 1 1148_CR57 H Tremlett (1148_CR63) 2016; 363 TM Dantoft (1148_CR29) 2017; 9 C Wen (1148_CR34) 2017; 18 N LaPierre (1148_CR46) 2019; 20 A Haghikia (1148_CR19) 2015; 43 A Duscha (1148_CR22) 2020; 180 |
| References_xml | – volume: 500 start-page: 541 year: 2013 ident: 1148_CR36 publication-title: Nature doi: 10.1038/nature12506 – volume: 44 start-page: D457 year: 2016 ident: 1148_CR39 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkv1070 – volume: 147 start-page: 212 year: 2016 ident: 1148_CR62 publication-title: Immunology. doi: 10.1111/imm.12552 – volume: 139 start-page: 208 year: 2019 ident: 1148_CR20 publication-title: Acta Neurol Scand doi: 10.1111/ane.13045 – volume: 29 start-page: 71 year: 2011 ident: 1148_CR16 publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-031210-101312 – volume: 464 start-page: 59 year: 2010 ident: 1148_CR9 publication-title: Nature. doi: 10.1038/nature08821 – volume: 12 year: 2021 ident: 1148_CR23 publication-title: Front Immunol doi: 10.3389/fimmu.2021.661493 – ident: 1148_CR43 – volume: 600 start-page: 500 year: 2021 ident: 1148_CR52 publication-title: Nature. doi: 10.1038/s41586-021-04177-9 – volume: 479 start-page: 538 year: 2011 ident: 1148_CR14 publication-title: Nature doi: 10.1038/nature10554 – volume: 391 start-page: 1622 year: 2018 ident: 1148_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(18)30481-1 – volume: 363 start-page: 153 year: 2016 ident: 1148_CR63 publication-title: J Neurol Sci doi: 10.1016/j.jns.2016.02.042 – volume: 44 start-page: D286 year: 2016 ident: 1148_CR40 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkv1248 – volume: 35 start-page: 1544 year: 2019 ident: 1148_CR37 publication-title: Bioinformatics. doi: 10.1093/bioinformatics/bty830 – volume: 12 start-page: 59 year: 2015 ident: 1148_CR42 publication-title: Nat Methods doi: 10.1038/nmeth.3176 – volume: 7 start-page: 12015 year: 2016 ident: 1148_CR58 publication-title: Nat Commun doi: 10.1038/ncomms12015 – ident: 1148_CR53 – volume: 43 start-page: 622 year: 2020 ident: 1148_CR13 publication-title: Trends Neurosci doi: 10.1016/j.tins.2020.06.002 – ident: 1148_CR48 – volume: 1863 start-page: 958 year: 2018 ident: 1148_CR60 publication-title: Biochim Biophys Acta Mol Cell Biol Lipids doi: 10.1016/j.bbalip.2018.05.009 – ident: 1148_CR38 doi: 10.15454/FLANUP – volume: 102 start-page: 500 year: 2013 ident: 1148_CR33 publication-title: Genomics doi: 10.1016/j.ygeno.2013.07.011 – ident: 1148_CR7 – ident: 1148_CR69 – volume: 389 start-page: 1347 year: 2017 ident: 1148_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(16)32388-1 – volume: 19 start-page: 179 year: 2020 ident: 1148_CR10 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30356-4 – volume: 81 start-page: 369 year: 2017 ident: 1148_CR27 publication-title: Ann Neurol doi: 10.1002/ana.24901 – volume: 136 start-page: 168 year: 2017 ident: 1148_CR6 publication-title: Acta Neurol Scand doi: 10.1111/ane.12712 – ident: 1148_CR51 doi: 10.1007/978-1-4939-8850-1 – volume: 7 year: 2020 ident: 1148_CR55 publication-title: Front Nutr doi: 10.3389/fnut.2020.610946 – volume: 97 start-page: 742 year: 2018 ident: 1148_CR3 publication-title: Neuron doi: 10.1016/j.neuron.2018.01.021 – volume: 64 start-page: 2346 year: 2014 ident: 1148_CR61 publication-title: Int J Syst Evol Microbiol doi: 10.1099/ijs.0.055095-0 – volume: 114 start-page: 10719 year: 2017 ident: 1148_CR15 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1711233114 – volume: 43 start-page: D571 year: 2015 ident: 1148_CR47 publication-title: Nucleic Acids Res doi: 10.1093/nar/gku1207 – volume: 11 start-page: 379 year: 2020 ident: 1148_CR56 publication-title: Front Immunol doi: 10.3389/fimmu.2020.00379 – volume: 17 year: 2021 ident: 1148_CR54 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1009442 – ident: 1148_CR71 – volume: 20 start-page: 423 year: 2019 ident: 1148_CR46 publication-title: BMC Genomics doi: 10.1186/s12864-019-5699-9 – ident: 1148_CR50 – volume: 29 start-page: 41 year: 2001 ident: 1148_CR41 publication-title: Nucleic Acids Res doi: 10.1093/nar/29.1.41 – volume: 43 start-page: 817 year: 2015 ident: 1148_CR19 publication-title: Immunity doi: 10.1016/j.immuni.2015.09.007 – volume: 11 year: 2020 ident: 1148_CR18 publication-title: Front Immunol doi: 10.3389/fimmu.2020.578648 – ident: 1148_CR49 – volume: 9 start-page: 357 year: 2012 ident: 1148_CR35 publication-title: Nat Methods doi: 10.1038/nmeth.1923 – ident: 1148_CR12 doi: 10.1172/JCI143774 – volume: 145 start-page: 569 issue: 2 year: 2022 ident: 1148_CR67 publication-title: Brain. doi: 10.1093/brain/awab320 – volume: 35 start-page: 1069 year: 2017 ident: 1148_CR30 publication-title: Nat Biotechnol doi: 10.1038/nbt.3960 – volume: 28 start-page: 1507 year: 2019 ident: 1148_CR26 publication-title: Cell Transplant doi: 10.1177/0963689719873890 – volume: 76 year: 2022 ident: 1148_CR24 publication-title: EBioMedicine. doi: 10.1016/j.ebiom.2021.103798 – volume: 8 start-page: 1867 year: 2021 ident: 1148_CR21 publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.51441 – ident: 1148_CR70 – ident: 1148_CR64 doi: 10.1111/nmo.14326 – volume: 1 start-page: 16088 year: 2016 ident: 1148_CR44 publication-title: Nat Microbiol doi: 10.1038/nmicrobiol.2016.88 – ident: 1148_CR32 – volume: 12 year: 2021 ident: 1148_CR66 publication-title: Front Immunol doi: 10.3389/fimmu.2021.676016 – volume: 9 start-page: 127 year: 2017 ident: 1148_CR29 publication-title: Clin Epidemiol doi: 10.2147/CLEP.S129335 – volume: 18 start-page: 142 year: 2017 ident: 1148_CR34 publication-title: Genome Biol doi: 10.1186/s13059-017-1271-6 – volume: 19 start-page: 317 year: 2021 ident: 1148_CR65 publication-title: J Transl Med doi: 10.1186/s12967-021-02995-z – volume: 216 start-page: 20 year: 2019 ident: 1148_CR11 publication-title: J Exp Med doi: 10.1084/jem.20180448 – volume: 4 start-page: 623 year: 2019 ident: 1148_CR45 publication-title: Nat Microbiol doi: 10.1038/s41564-018-0337-x – volume: 11 start-page: 1612 year: 2020 ident: 1148_CR59 publication-title: Nat Commun doi: 10.1038/s41467-020-15457-9 – volume: 378 start-page: 169 year: 2018 ident: 1148_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra1401483 – volume: 17 year: 2022 ident: 1148_CR68 publication-title: PLoS One doi: 10.1371/journal.pone.0264556 – volume: 83 start-page: 278 year: 2014 ident: 1148_CR4 publication-title: Neurology. doi: 10.1212/WNL.0000000000000560 – volume: 17 start-page: 162 year: 2018 ident: 1148_CR28 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30470-2 – volume: 10 start-page: 462 year: 2019 ident: 1148_CR17 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00462 – ident: 1148_CR57 doi: 10.1126/sciadv.abd4595 – volume: 37 start-page: 101427 year: 2020 ident: 1148_CR25 publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2019.101427 – volume: 26 start-page: 397 year: 2020 ident: 1148_CR8 publication-title: Mult Scler doi: 10.1177/1352458519872664 – volume: 180 start-page: 1067 year: 2020 ident: 1148_CR22 publication-title: Cell doi: 10.1016/j.cell.2020.02.035 – ident: 1148_CR31 |
| SSID | ssj0064247 |
| Score | 2.5585306 |
| Snippet | Background
Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults.... Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is... Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults.... Background : Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young... Abstract Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Bacteria Bioinformatics Biological diversity Biomedical and Life Sciences Biomedicine Cancer Research Cytokines Development and progression Faecalibacterium prausnitzii Feces - microbiology Gastrointestinal Microbiome Gene expression Genetics Gordonibacter urolithinfaciens Gut microbiota Human Genetics Humans Inflammation Life Sciences Medicine/Public Health Metabolomics Microbiota Microbiota (Symbiotic organisms) Multiple Sclerosis Shotgun sequencing Systems Biology Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokL4s2WAgYhcYCosZ34cVxQqx6qigOg3qzYTmikkqImu1L_PTN2EhEqlQvXeJw4k8_2jDPzDSHvShOK3POQOe7w6CbIzDSly7wH-OTSuTJmeH8_Vicn-vTUfPmj1BfGhCV64KS4fQM7iAqGNUbyonKVKxvhRSmM05KFmELOc2UmZyqtwWBUF2pKkdFyv2cI5Qwj16MDkLHFNhTZ-uc1-fYZhkRetzevh03-9e80bkmHD8j90Zak6_QOD8mtuntE7qbqklePyQFAgP7YDPRnm9iWhoq2HZ1CCGkPnWBwbU-30WGmeCZLxz82FBMesK7EE_Lt8ODr56NsrJqQebBthqzRFfe111XNC_DeXKVcw43UOpgCrAUeWJMz1wQpFPd5XbhahYYJB75MyEXViKdkp7vo6ueEVhLuEHxwaAR43TiwLURZl3lQwvPKrQiblGj9SCmOlS3ObXQttLRJ8RYUb6PiLVuRD3OfX4lQ40bpT_htZkkkw44XACJ2hIj9F0RW5DV-WZsyS-cpbddKIPsh7OEr8j5K4KSGF_DVmJsAakB6rIXk3kISJqNfNL8F9CyGe7Q-tngNydUw6GgL43kzgctifwxz6-qLTW85Hiqpkkm9Is8S2OZ7CSnzQhXQohYwXDxs2dK1Z5Ew3GhWMAU9P06AteNK1d-g-93_ofsX5B4HszAeWpV7ZGe43NQvyR2_Hdr-8lWctL8B1gpAvg priority: 102 providerName: Directory of Open Access Journals |
| Title | The gut microbiota in multiple sclerosis varies with disease activity |
| URI | https://link.springer.com/article/10.1186/s13073-022-01148-1 https://www.ncbi.nlm.nih.gov/pubmed/36604748 https://www.proquest.com/docview/2761975168 https://hal.inrae.fr/hal-04300520 https://pubmed.ncbi.nlm.nih.gov/PMC9814178 https://doaj.org/article/92667d91f9624abab5f3c3539b861d21 |
| Volume | 15 |
| WOSCitedRecordID | wos000909533900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RBZ dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: M7P dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 1756-994X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0064247 issn: 1756-994X databaseCode: RSV dateStart: 20090101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0GIbSLzw_VEYxSAkHlhEbCe289ihTkMaVTVgKk9WbCdbpS1FTVuJf8-dk1QKQ5PgJQ_2nRNfzue7892ZkHdp5pPYcR9ZbtF142WUlamNnAP2iaW1acjwPjtRk4mezbJpmxRWd9Hu3ZFkkNRhWWv5sWbIjhFGnwclPgKbZw-2O40XNpx-PevkLyjUierSY_6K19uCQqX-rTzeucBwyOu65vWQyT_OTcN2dHT__ybygNxr1U86avjlIblVVI_IneZCyl-PyRi4hp6vV_Rq3hRoWuV0XtEu6pDWgARzmtd0E2xsim5c2h7yUMyRwKsonpDvR-Nvn46j9qKFyIE6tIpKnXNXOJ0XPAGDz-bKljyTWvssAQWDe1bGzJZeCsVdXCS2UL5kwoL542ORl-Ip2a0WVfGc0FzCCN55i3qD06UFdUSkRRp7JRzP7YCwjvbGtVXI8TKMSxOsES1NQx4D5DGBPIYNyIctzs-mBseN0If4S7eQWD87NCyW56ZdjiYDvUT5jJWZ5Eluc5uWwolUZFZL5jkM8hoZwjTJqFspYEZKYMFE2PYH5H2AQDkAE3B5m84AZMCKWj3I_R4krF_X634LTNf73OPRicE2rMeGcUob-J43HU8axMfIuKpYrGvD0Q-lUib1gDxreHQ7lpAyTlQCParHvb2X9Xuq-UWoMZ5pljAFmAcdD5tWuNU30P7Fv4G_JHc56IzBo5Xuk93Vcl28IrfdZjWvl0Oyo2YqPPWQ7B2OJ9PTYXCZDDFAdwpt089fpj-GYfX_BtvTTF0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9QwDI9ggOCF74-DwQJC4gEqmqRN0scDbTrEcUIwpr1FTdJulbYeuvZO4r_HTtuTytAkeG3stHEd5-fEdgh5nWY-iR33keUWt268jLIytZFzoD6xtDYNGd5Hc7VY6OPj7GufFNYM0e7DkWSw1GFaa_m-YaiOEUafBxAfgc9zLYEVCyvmf_t-NNhfANSJGtJj_so3WoJCpf6tPb56iuGQF7HmxZDJP85Nw3J0cOf_BnKX3O7hJ512-nKPXCnq--RGdyHlrwdkH7SGnqxbel51BZranFY1HaIOaQNMMKaqoZvgY1PcxqX9IQ_FHAm8iuIh-XGwf_hxFvUXLUQO4FAblTrnrnA6L3gCDp_NlS15JrX2WQIAg3tWxsyWXgrFXVwktlC-ZMKC--NjkZfiEdmpl3XxhNBcQg_eeYu4wenSAhwRaZHGXgnHczshbJC9cX0VcrwM48wEb0RL04nHgHhMEI9hE_J2y_Ozq8FxKfUH_KVbSqyfHR4sVyemn44mA1yifMbKTPIkt7lNS-FEKjKrJfMcOtlDhTBdMurWCpipElgwEZb9CXkTKNAOwABc3qczgBiwotaIcndECfPXjZpfgdKNPnc2nRt8hvXYME5pA9_zctBJg_wYGVcXy3VjOO5DqZRJPSGPOx3d9iWkjBOVQIsaae_oZeOWujoNNcYzzRKmgPPdoMOmN27NJbJ_-m_ke-Tm7PDL3Mw_LT4_I7c44Mewu5Xukp12tS6ek-tu01bN6kWY4b8Bx1tIPA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDI9gfIgXvj8OBisIiQeo1iRtkj4esNMQp9MkYNpb1CTNVgl607V3Ev89dtqeKEOTEK-NnTaO4_6c2A4hr7PcpYllLjbM4NaNE3HuMxNbC-qTCGOykOF9PJeLhTo5yY9-y-IP0e7DkWSX04BVmup2_9z5bokrsd9QVM0YI9EDoI_B_7mWYiA9-utfjgdbDOA6lUOqzF_5Rr-jULV_a5uvnmFo5EXceTF88o8z1PBrmt35_0HdJbd7WBpNOz26R66U9X1yo7uo8ucDcgDaFJ2u2-hH1RVuaouoqqMhGjFqgAnGVzXRJvjeEW7vRv3hT4S5E3hFxUPybXbw9cNh3F_AEFuASW3sVcFsaVVRshQcQVNI41kulHJ5CsCDOeoTarwTXDKblKkppfOUG3CLXMILzx-RnXpZl09IVAjowVlnEE9Y5Q3AFJ6VWeIkt6wwE0KHedC2r06Ol2R818FLUUJ34tEgHh3Eo-mEvN3ynHe1OS6lfo_Tu6XEutrhwXJ1qvtlqnPAK9Ll1OeCpYUpTOa55RnPjRLUMehkD5VDd0mqW-ugp5JjIUWAAxPyJlCgfYAB2KJPcwAxYKWtEeXuiBLWtR01vwIFHH3u4XSu8RnWacP4pQ18z8tBPzXyY8RcXS7XjWa4PyUzKtSEPO70ddsXFyJJZQotcqTJo5eNW-rqLNQezxVNqQTOd4M-697oNZfI_um_ke-Rm0cfZ3r-afH5GbnFAFaGTa9sl-y0q3X5nFy3m7ZqVi_CYv8FFN9RIA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+gut+microbiota+in+multiple+sclerosis+varies+with+disease+activity&rft.jtitle=Genome+medicine&rft.au=Thirion%2C+Florence&rft.au=Sellebjerg%2C+Finn&rft.au=Fan%2C+Yong&rft.au=Lyu%2C+Liwei&rft.date=2023-01-05&rft.issn=1756-994X&rft.eissn=1756-994X&rft.volume=15&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1186%2Fs13073-022-01148-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-994X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-994X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-994X&client=summon |